2026-04-14T16:53:16Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/820082026-03-20T11:42:25Zcom_10324_1134com_10324_931com_10324_894col_10324_1213

Lamo-Espinosa, José María Prósper, Felipe Blanco, Juan Francisco Sánchez Guijo, Fermín Alberca Zaballos, María Mercedes García Diaz, Verónica González-Vallinas Garrachón, Margarita García-Sancho Martín, Francisco Javier 2026-01-22T11:27:07Z 2026-01-22T11:27:07Z 2021 J Transl Med, Diciembre 2021, vol. 19, n. 1, p. 506. 1479-5876 https://uvadoc.uva.es/handle/10324/82008 10.1186/s12967-021-03160-2 506 1 Journal of Translational Medicine 19 1479-5876 Producción Científica Knee osteoarthritis is the most prevalent joint disease and a frequent cause of pain, functional loss and disability. Conventional treatments have demonstrated only modest clinical benefits whereas cell-based therapies have shown encouraging results, but important details, such as dose needed, long-term evolution or number of applications required are scarcely known. Here we have reanalyzed results from two recent pilot trials with autologous bone marrow-derived mesenchymal stromal cells using the Huskisson plot to enhance quantification of efficacy and comparability. We find that cell doses of 10, 40 and 100 million autologous cells per knee provided quite similar healing results and that much of the effect attained 1 year after cell application remained after 2 and 4 years. These results are encouraging because they indicate that, apart from safety and simplicity: (i) the beneficial effect is both significant and sizeable, (ii) it can be achieved with a single injection of cells, and (iii) the effect is perdurable for years.Trial registration: EudraCT 2009-017405-11; NCT02123368. Registered 25 April 2014-Prospectively registered, https://clinicaltrials.gov/ct2/show/NCT02123368?term=02123368&draw=2&rank=1. This work was supported by Red de Terapia Celular of Instituto de Salud Carlos III (RETIC TerCel, RD16/0011/0003, 0005, and 0015; PIC18/00001), Centro en Red de Medicina Regenerativa de Castilla y León, and Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Escalera de Excelencia, Junta de Castilla y León (Ref. CLU-2019-02). The European Union co-financed these grants through the European Regional Development Fund. M.G.V. was supported by a Juan de la Cierva Incorporation Fellowship. application/pdf eng BioMed Central (BMC) info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 Internacional Intraarticular injection Mesenchymal stem cells Osteoarthritis Regenerative medicine Stem cell therapy Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://link.springer.com/article/10.1186/s12967-021-03160-2 SI